Ralliant (NYSE:RAL) Stock Rating Upgraded by Vertical Research

Ralliant (NYSE:RAL) was upgraded by investment analysts at Vertical Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage presently has a $45.00 price target on the stock. Vertical Research’s target price would indicate a potential upside of 13.92% from the stock’s previous close.

Other research analysts have also issued reports about the company. Barclays raised their price objective on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada raised their target price on Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a report on Friday, November 7th. Truist Financial initiated coverage on Ralliant in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Finally, Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $53.00 to $61.00 in a research note on Monday, December 8th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.30.

Ralliant Trading Up 2.9%

NYSE RAL opened at $39.50 on Friday. The firm has a market capitalization of $4.46 billion and a price-to-earnings ratio of 31.10. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.03 and a current ratio of 0.84. Ralliant has a one year low of $37.27 and a one year high of $57.02. The company’s 50 day moving average price is $51.52 and its 200 day moving average price is $46.72.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. Ralliant’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Institutional Trading of Ralliant

Several institutional investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB acquired a new position in shares of Ralliant during the second quarter valued at $29,477,000. Cullen Frost Bankers Inc. bought a new stake in Ralliant in the 2nd quarter valued at about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Ralliant during the 2nd quarter valued at about $1,410,000. JPMorgan Chase & Co. acquired a new position in Ralliant during the 2nd quarter valued at about $18,494,000. Finally, Allspring Global Investments Holdings LLC grew its position in Ralliant by 5,269.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock worth $14,000,000 after purchasing an additional 311,134 shares during the last quarter.

Key Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.